| 000 | 01253 a2200337 4500 | ||
|---|---|---|---|
| 005 | 20250513204620.0 | ||
| 264 | 0 | _c20000616 | |
| 008 | 200006s 0 0 eng d | ||
| 022 | _a1174-5886 | ||
| 024 | 7 |
_a10.2165/00126839-199902050-00008 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 245 | 0 | 0 |
_aSevirumab. Protovir, MSL 109, EV2 7, SDZ MSL 109. _h[electronic resource] |
| 260 |
_bDrugs in R&D _cNov 1999 |
||
| 300 |
_a315-7 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xpharmacokinetics |
| 650 | 0 | 4 |
_aAntiviral Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aBone Marrow Transplantation _xadverse effects |
| 650 | 0 | 4 | _aClinical Trials, Phase I as Topic |
| 650 | 0 | 4 | _aClinical Trials, Phase II as Topic |
| 650 | 0 | 4 |
_aCytomegalovirus _xdrug effects |
| 650 | 0 | 4 |
_aCytomegalovirus Infections _xprevention & control |
| 650 | 0 | 4 |
_aCytomegalovirus Retinitis _xdrug therapy |
| 650 | 0 | 4 |
_aDrugs, Investigational _xpharmacokinetics |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMicrobial Sensitivity Tests |
| 650 | 0 | 4 | _aRabbits |
| 773 | 0 |
_tDrugs in R&D _gvol. 2 _gno. 5 _gp. 315-7 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.2165/00126839-199902050-00008 _zAvailable from publisher's website |
| 999 |
_c10682220 _d10682220 |
||